Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558640 | 0.93 | KDM4E (0.50) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL3888792 | 0.88 | KDM4E (0.50) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL3556165 | 0.82 | SLC6A9 (0.56) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL18274654 | 0.81 | SLC6A9 (0.59) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL3997790 | 0.81 | OPRM1 (0.51) | SLC6A9KDM4E | |
| SCHEMBL3559166 | 0.81 | KDM4E (0.46) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL8279640 | 0.80 | SLC6A9 (0.66) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL16549656 | 0.79 | ADRA1A (0.55) | — | |
| SCHEMBL3561259 | 0.79 | SLC6A9 (0.56) | SLC6A9KDM4EHSD17B10 | |
| SCHEMBL6887265 | 0.78 | ADRA1A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1942733-B1 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7834031-B2 | Radiolabeled glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| EP-1729772-A4 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1942733-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| WO-2007041025-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1729772-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck and Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | SLC6A5, SLC1A5, SLC1A3 | SLC6A9 6/4885KDM4E 4146/4885HSD17B10 1654/4885 |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 33/4885KDM4E 3789/4885HSD17B10 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.